ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

IRWD vs GERN // DIVIDEND YIELD & FCF PAYOUT SAFETY

Ironwood Pharmaceuticals Inc. (Class A) (NASDAQ) VS. Geron Corporation (NASDAQ) • 15-METRIC TALLY: IRWD 4 — GERN 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IRWD VS. GERN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC IRWD GERN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 85.00% -20.20% +105.20 IRWD /roic <GO>
EV/EBITDA & P/E Valuation 3.9x — — TIE /valuation <GO>
Free Cash Flow Yield 21.23% -18.27% +39.50 IRWD /fcf-yield <GO>
Operating Margin 33.30% — — TIE /operating-margins <GO>
Net Profit Margin 8.10% — — TIE /net-margins <GO>
Revenue Growth (YoY) -15.70% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety ACTIVE 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 7/9 3/9 +4.00 IRWD /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 46.2 30.6 +15.60 IRWD /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 23.2x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $598.2M $607.9M -$9.7M GERN /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR IRWD REV GERN REV IRWD GROSS % GERN GROSS % IRWD FCF GERN FCF
FY 2025 $296.2M $0 — — $127.0M -$111.0M
FY 2024 $351.4M $0 — — $103.4M -$219.3M
FY 2023 $442.7M $237.0K — — $183.4M -$167.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IRWD // BETA —
GERN // BETA —